The brand new three-year settlement for the provision of regular supply plasma from Kamada’s plasma assortment facilities in Texas will produce about $50 million in income over three years.
Israeli biopharmaceutical firm Kamada (Nasdaq: KMDA; TASE: KMDA) as we speak introduced an settlement to produce plasma to a number one biopharmaceutical firm centered on plasma-derived therapies. The brand new three-year settlement for the provision of regular supply plasma from Kamada’s plasma assortment facilities in Texas will produce about $50 million in income over three years. Preliminary business gross sales underneath the settlement are anticipated to be recorded within the fourth quarter of 2026.
RELATED ARTICLES
Kamada has a portfolio of marketed merchandise indicated for uncommon and severe situations within the specialty plasma-derived discipline. The corporate’s FDA-approved assortment facilities in Houston and San Antonio are designed to gather regular supply plasma and specialty plasma. Every heart helps a deliberate capability of roughly 50,000 liters per yr at full capability.
Kamada CEO Amir London mentioned, “We’re very happy to announce this provide settlement which validates the funding we made in our U.S.-based state-of-the-art plasma assortment facilities. This vital settlement helps each our vertical-integration technique, in addition to our multi-year income progress aims. We’re happy with the tempo of our assortment ramp-up actions, and we thank our groups in Texas for his or her wonderful work.”
In pre-market buying and selling Kamada’s share worth is up 4.26% at $7.35. Yesterday, the share worth rose 2.03%, giving a market cap of $406.745 million.
Printed by Globes, Israel enterprise information – en.globes.co.il – on July 20, 2026.
© Copyright of Globes Writer Itonut (1983) Ltd., 2026.
Kamada credit score: Kamada
Â
Â
